Global and India Personalized Cancer Medicine Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Personalized Cancer Medicine Market Report & Forecast 2024-2034
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
ImmunotherapiesWhile not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
The global Personalized Cancer Medicine revenue was US$ 161690 million in 2022 and is forecast to a readjusted size of US$ 350430 million by 2029 with a CAGR of 12.5% during the review period (2024-2034).
In India, the Personalized Cancer Medicine revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2024-2034.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
This report focuses on global and India Personalized Cancer Medicine market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Personalized Cancer Medicine will continue to grow rapidly in the future.
Global Personalized Cancer Medicine Scope and Market Size
Personalized Cancer Medicine market is segmented in regional and country level, by players, by Method and by Application. Companies, stakeholders, and other participants in the global Personalized Cancer Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Method and by Application for the period 2018-2029.
For India market, this report focuses on the Personalized Cancer Medicine market size by players, by Method and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Method
Cancer Immunotherapy
Targeted Therapy
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Personalized Cancer Medicine definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by method, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Personalized Cancer Medicine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Personalized Cancer Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by method, by application and by country revenue for each segment.
Chapter 7EMEA by method, by application and by region, revenue for each segment.
Chapter 8China by method, by application revenue for each segment.
Chapter 9APAC (excluding China) by method, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Personalized Cancer Medicine revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
ImmunotherapiesWhile not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
The global Personalized Cancer Medicine revenue was US$ 161690 million in 2022 and is forecast to a readjusted size of US$ 350430 million by 2029 with a CAGR of 12.5% during the review period (2024-2034).
In India, the Personalized Cancer Medicine revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2024-2034.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
This report focuses on global and India Personalized Cancer Medicine market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Personalized Cancer Medicine will continue to grow rapidly in the future.
Global Personalized Cancer Medicine Scope and Market Size
Personalized Cancer Medicine market is segmented in regional and country level, by players, by Method and by Application. Companies, stakeholders, and other participants in the global Personalized Cancer Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Method and by Application for the period 2018-2029.
For India market, this report focuses on the Personalized Cancer Medicine market size by players, by Method and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Method
Cancer Immunotherapy
Targeted Therapy
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Personalized Cancer Medicine definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by method, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Personalized Cancer Medicine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Personalized Cancer Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by method, by application and by country revenue for each segment.
Chapter 7EMEA by method, by application and by region, revenue for each segment.
Chapter 8China by method, by application revenue for each segment.
Chapter 9APAC (excluding China) by method, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Personalized Cancer Medicine revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices